DCAL vs ERIS: Stock Comparison

DISHMAN CARBO AMCIS vs ERIS LIFESCIENCESUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

ERIS LIFESCIENCES is the larger company by market capitalisation. DISHMAN CARBO AMCIS shows faster revenue growth and lower leverage, while ERIS LIFESCIENCES shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

DCAL leads 4; ERIS leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

DCALERIS

Valuation lens

What price are you paying?

Market CapContext only
₹2,723 Cr
₹18,299 Cr
P/E RatioERIS has the lower reading
172.04x
28.56x
P/B RatioDCAL has the lower reading
0.42x
4.74x
EPSERIS has the higher reading
₹-1.53
₹3.49
Book ValueContext only
₹425.87
₹281.12
Dividend YieldERIS has the higher reading
0%
0.55%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ERIS is the larger company
₹18,299 Cr vs ₹2,723 Cr
P/E Ratio
ERIS has a lower P/E
28.56x vs 172.04x
P/B Ratio
DCAL has a lower P/B
0.42x vs 4.74x
EPS
ERIS has higher earnings per share
₹3.49 vs ₹-1.53
Dividend Yield
ERIS has a higher dividend yield
0.55% vs 0%
Revenue Growth (TTM YoY)
DCAL has faster revenue growth
18.9% vs 7.1%
EPS Growth (TTM YoY)
ERIS has faster EPS growth
200% vs -49.5%
Qtr Sales Growth
ERIS has stronger quarterly sales growth
-49.16% vs -91.58%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDCALERIS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDCALERIS
Live Price₹174.38₹1,321.7
Day Change-1.47%1.4%
Volume1.23 L69,111
52-Week High₹321.95₹1,797.6
52-Week Low₹128.5₹1,200
Distance from 52W High-45.84%-26.47%

Valuation

MetricDCALERIS
Market Cap₹2,723 Cr₹18,299 Cr
P/E Ratio172.04x28.56x
P/B Ratio0.42x4.74x
EPS₹-1.53₹3.49
Book Value₹425.87₹281.12
Dividend Yield0%0.55%

Growth

MetricDCALERIS
Revenue Growth (TTM YoY)18.9%7.1%
EPS Growth (TTM YoY)-49.5%200%
Qtr Sales Growth-91.58%-49.16%
Qtr Profit Growth58.69%-66.3%

Profitability & Leverage

MetricDCALERIS
ROE1.46%16.62%
ROCE1.52%13.51%
Net Margin2.51%19.89%
Operating Margin9.52%26.56%
Debt to Equity0.42x0.59x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricDCALERIS
Promoter Holding59.32%54.14% 0.22 pp
FII Holding6.86% 0.59 pp5.75% 0.64 pp
DII Holding2.07% 0.44 pp20.72% 0.37 pp
Public Holding31.75% 0.15 pp19.4% 0.07 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DISHMAN CARBO AMCIS and ERIS LIFESCIENCES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.